Šablon:HumanizovaniMonoklonali-lat

p r u Humanizovana monoklonalna antitela ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (imunski sistem)	imunosupresivni: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-imunosupresivni: Ibalizumab^†
"-bazu-" (bakterijski)	Tefibazumab^†
"-cizu-" (kardiovaskularni)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervni sistem)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toksazu-" (toksin kao meta)	Urtoksazumab
"-vizu-" (viralni)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin kao meta)	Lebrikizumab
"-anibizu-" (inhibitor angiogeneze)	Ranibizumab
^†U kliničkim ispitivanjima. ^§Nije bio u prodaji.